{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T03:47:43Z","timestamp":1776052063908,"version":"3.50.1"},"reference-count":47,"publisher":"Portland Press Ltd.","issue":"2","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,3,1]]},"abstract":"<jats:p>Enzyme replacement therapy for MPS IIIB (mucopolysaccharidosis type\u00a0IIIB; also known as Sanfilippo B syndrome) has been hindered by inadequate mannose 6 phosphorylation and cellular uptake of rhNAGLU (recombinant human \u03b1-N-acetylglucosaminidase). We expressed and characterized a modified rhNAGLU fused to the receptor-binding motif of IGF-II (insulin-like growth factor 2) (rhNAGLU\u2013IGF-II) to enhance its ability to enter cells using the cation-independent mannose 6-phosphate receptor, which is also the receptor for IGF-II (at a different binding site). RhNAGLU\u2013IGF-II was stably expressed in CHO (Chinese-hamster ovary) cells, secreted and purified to apparent homogeneity. The Km and pH optimum of the fusion enzyme was similar to those reported for rhNAGLU. Both intracellular uptake and confocal microscopy suggested that MPS IIIB fibroblasts readily take up the fusion enzyme via receptor-mediated endocytosis that was inhibited significantly (P&amp;lt;0.001) by the monomeric IGF-II peptide. Glycosaminoglycan storage was reduced by 60% (P&amp;lt;0.001) to near background levels in MPS IIIB cells after treatment with rhNAGLU\u2013IGF-II, with half-maximal correction at concentrations of 3\u201312 pM. A similar cellular uptake mechanism via the IGF-II receptor was also demonstrated in two different brain tumour-derived cell lines. Fusion of rhNAGLU to IGF-II enhanced its cellular uptake while maintaining enzymatic activity, supporting its potential as a therapeutic candidate for treating MPS IIIB.<\/jats:p>","DOI":"10.1042\/bj20130845","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T09:58:17Z","timestamp":1385459897000},"page":"281-289","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of \u03b1-<i>N<\/i>-acetylglucosaminidase to mucopolysaccharidosis type\u00a0IIIB fibroblasts"],"prefix":"10.1042","volume":"458","author":[{"given":"Shih-hsin","family":"Kan","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa\u00a0A.","family":"Troitskaya","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn\u00a0S.","family":"Sinow","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karyn","family":"Haitz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda\u00a0K.","family":"Todd","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariana","family":"Di Stefano","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven\u00a0Q.","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia\u00a0I.","family":"Dickson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigette\u00a0L.","family":"Tippin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2014,2,14]]},"reference":[{"key":"2021112216013514600_B1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10545-008-0838-5","article-title":"Sanfilippo syndrome: a mini review","volume":"31","author":"Valstar","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"2021112216013514600_B2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharisosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2021112216013514600_B3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"2021112216013514600_B4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study","volume":"148","author":"Harmatz","year":"2006","journal-title":"J. Pediatr."},{"key":"2021112216013514600_B5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2021112216013514600_B6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"2021112216013514600_B7","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"2021112216013514600_B8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2006.12.012","article-title":"Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid","volume":"91","author":"Dickson","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"2021112216013514600_B9","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1096\/fj.06-6169com","article-title":"Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy","volume":"21","author":"Lee","year":"2007","journal-title":"FASEB J."},{"key":"2021112216013514600_B10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2006.10.005","article-title":"Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice","volume":"90","author":"Hemsley","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"2021112216013514600_B11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/mt.2008.9","article-title":"Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis","volume":"16","author":"Chang","year":"2008","journal-title":"Mol. Ther."},{"key":"2021112216013514600_B12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.expneurol.2008.10.021","article-title":"Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann\u2013Pick A disease","volume":"215","author":"Dodge","year":"2009","journal-title":"Exp. Neurol."},{"key":"2021112216013514600_B13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.expneurol.2011.04.019","article-title":"Treatment of canine fucosidosis by intracisternal enzyme infusion","volume":"230","author":"Kondagari","year":"2011","journal-title":"Exp. Neurol."},{"key":"2021112216013514600_B14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1006\/mgme.2000.3095","article-title":"Short-term enzyme replacement in the murine model of Sanfilippo syndrome type\u00a0B","volume":"71","author":"Yu","year":"2000","journal-title":"Mol. Genet. Metab."},{"key":"2021112216013514600_B15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/prep.2000.1361","article-title":"Expression and characterization of human recombinant and \u03b1-N-actylglucosaminidase","volume":"21","author":"Weber","year":"2001","journal-title":"Prot. Expr. Purif."},{"key":"2021112216013514600_B16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/prep.2000.1230","article-title":"Purification and characterization of recombinant human \u03b1-N-acetylglucosaminidase secreted by Chinese hamster ovary cells","volume":"19","author":"Zhao","year":"2000","journal-title":"Prot. Expr. Purif."},{"key":"2021112216013514600_B17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/mthe.2001.0514","article-title":"Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery","volume":"5","author":"Fu","year":"2002","journal-title":"Mol. Ther."},{"key":"2021112216013514600_B18","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1523\/JNEUROSCI.3558-04.2004","article-title":"Improved behavior and neuropathology in the mouse model of Sanfilippo type\u00a0IIIB disease after adeno-associated virus-mediated gene transfer in the striatum","volume":"24","author":"Cressant","year":"2004","journal-title":"J. Neurosci."},{"key":"2021112216013514600_B19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ymgme.2004.06.004","article-title":"Retrovirally transduced bone marrow has a therapeutic effect on brain in the mouse model of mucopolysaccharidosis IIIB","volume":"82","author":"Zheng","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"2021112216013514600_B20","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.gt.3302961","article-title":"Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice","volume":"14","author":"Fu","year":"2007","journal-title":"Gene Ther."},{"key":"2021112216013514600_B21","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/gt.2009.85","article-title":"Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice","volume":"16","author":"McCarty","year":"2009","journal-title":"Gene Ther."},{"key":"2021112216013514600_B22","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/jgm.1480","article-title":"Restoration of central nervous system \u03b1-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type\u00a02 vector delivery","volume":"12","author":"Fu","year":"2010","journal-title":"J. Gene Med."},{"key":"2021112216013514600_B23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","article-title":"Sorting of lysosomal proteins","volume":"1793","author":"Braulke","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"2021112216013514600_B24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0304-4157(95)00004-B","article-title":"Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes","volume":"1241","author":"Hille-Rehfeld","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"key":"2021112216013514600_B25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.brainresrev.2003.11.002","article-title":"The insulin-like growth factor-II\/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system","volume":"44","author":"Hawkes","year":"2004","journal-title":"Brain Res. Rev."},{"key":"2021112216013514600_B26","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1073\/pnas.0308728100","article-title":"Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type\u00a0VII mice","volume":"101","author":"LeBowitz","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021112216013514600_B27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/rej.2009.0920","article-title":"New strategies for enzyme replacement therapy for lysosomal storage diseases","volume":"13","author":"Grubb","year":"2010","journal-title":"Rejuv. Res."},{"key":"2021112216013514600_B28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0008-6215(00)84698-4","article-title":"4-Methylumbelliferyl 2-acetamido-2-deoxy-\u03b1-D-glucopyranoside, a fluorogenic substrate for N-acetyl-\u03b1-D-glucosaminidase","volume":"96","author":"Chow","year":"1981","journal-title":"Carbohydr. Res."},{"key":"2021112216013514600_B29","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1016\/S0021-9258(19)45842-0","article-title":"The Hurler corrective factor. Purification and some properties","volume":"246","author":"Barton","year":"1971","journal-title":"J. Biol. Chem."},{"key":"2021112216013514600_B30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/prep.1994.1035","article-title":"Overexpression of the human lysosomal enzyme \u03b1-l-iduronidase in Chinese hamster ovary cells","volume":"5","author":"Kakkis","year":"1994","journal-title":"Prot. Expr. Purif."},{"key":"2021112216013514600_B31","doi-asserted-by":"crossref","first-page":"15908","DOI":"10.1073\/pnas.0808360105","article-title":"Aptamer-based endocytosis of a lysosomal enzyme","volume":"105","author":"Chen","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021112216013514600_B32","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1073\/pnas.93.12.6101","article-title":"The molecular basis of Sanfilippo syndrome type\u00a0B","volume":"93","author":"Zhao","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021112216013514600_B33","first-page":"285","article-title":"Serum \u03b1-N-acetylglucosaminidase: determination, characterization, and corrective activity in Sanfilippo B fibroblasts","volume":"13","author":"von Figura","year":"1975","journal-title":"Z. Klin. Chem. Klin. Biochem."},{"key":"2021112216013514600_B34","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1515\/bchm2.1978.359.2.1353","article-title":"Human placenta \u03b1-N-acetylglucosaminidase: purification, characterization and demonstration of multiple recognition forms","volume":"359","author":"Rohrborn","year":"1978","journal-title":"Hoppe Seylers Z. Physiol. Chem."},{"key":"2021112216013514600_B35","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/oxfordjournals.jbchem.a123668","article-title":"Purification and partial characterization of \u03b1-N-acetylglucosaminidase from human liver","volume":"110","author":"Sasaki","year":"1991","journal-title":"J. Biochem."},{"key":"2021112216013514600_B36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/345078a0","article-title":"A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting","volume":"345","author":"DeChiara","year":"1990","journal-title":"Nature"},{"key":"2021112216013514600_B37","doi-asserted-by":"crossref","first-page":"18013","DOI":"10.1074\/jbc.270.30.18013","article-title":"N-terminal deletion mutants of insulin-like growth factor-II (IGF-II) show Thr and Leu important for binding to insulin and IGF-I receptors and leu critical for all IGF-II functions","volume":"270","author":"Hashimoto","year":"1995","journal-title":"J. Biol. Chem."},{"key":"2021112216013514600_B38","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1210\/edrv.22.6.0452","article-title":"Distinct and overlapping functions of insulin and IGF-I receptors","volume":"22","author":"Nakae","year":"2001","journal-title":"Endo. Rev."},{"key":"2021112216013514600_B39","doi-asserted-by":"crossref","first-page":"43160","DOI":"10.1074\/jbc.M107778200","article-title":"Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated \u03b2-glucuronidase in the murine model of mucopolysaccharidosis VII","volume":"276","author":"Sands","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2021112216013514600_B40","first-page":"247","article-title":"Intrathecal recombinant human \u03b1-l-iduronidase alleviates spinal cord compression symptoms and is well-tolerated in attenuated MPS I patients","volume":"93","author":"Dickson","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"2021112216013514600_B41","article-title":"Intrathecal delivery of iduronate 2-sulfatase to the CNS of cynomolgous monkeys","volume-title":"American Society of Human Genetics 57th Annual Meeting","author":"Garcia","year":"2007"},{"key":"2021112216013514600_B42","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/ajmg.a.32294","article-title":"Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type\u00a0I and symptomatic spinal cord compression","volume":"146A","author":"Mu\u00f1oz-Rojas","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"2021112216013514600_B43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1460-9568.2009.06666.x","article-title":"Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease","volume":"29","author":"Hemsley","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"2021112216013514600_B44","first-page":"S118","article-title":"Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases","volume":"47","author":"Hemsley","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"2021112216013514600_B45","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/mt.2010.17","article-title":"Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB","volume":"18","author":"Heldermon","year":"2010","journal-title":"Mol. Ther."},{"key":"2021112216013514600_B46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2010.265","article-title":"Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes","volume":"19","author":"Ellinwood","year":"2011","journal-title":"Mol. Ther."},{"key":"2021112216013514600_B47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/458\/2\/281\/679177\/bj4580281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/458\/2\/281\/679177\/bj4580281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T22:47:09Z","timestamp":1637621229000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/458\/2\/281\/46813\/Insulin-like-growth-factor-II-peptide-fusion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,14]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bj20130845","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,14]]}}}